Scientists zap brains to unlock secrets of focus
NCT ID NCT04885322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses a weak electrical current applied to the scalp (tDCS) to see if it can improve attention and cognitive control in healthy adults and people with schizophrenia. Participants will perform thinking tasks while their brain activity is measured with EEG. The goal is to understand how different brain regions contribute to focus and memory, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- transcranial direct current stimulation (tDCS)
- What this could lead to
- If successful, this could help scientists understand how brain stimulation affects attention and thinking, potentially guiding future treatments for cognitive issues.
- What could go wrong
- This is a small, early-stage basic research study, not a treatment trial. It may not lead to any direct medical benefit, and results may not apply to real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imaging Research Center
RECRUITINGSacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test